Grants and Contributions:
Title:
Enhancing eradication of solid tumours using Site-Specific Immunomodulators and engineered cancer-specific T cells
Agreement Number:
924855
Agreement Value:
$153,855.00
Agreement Date:
Mar 1, 2019 - Jan 31, 2020
Description:
This project aims to generate preclinical data showing that solid tumours can be better accessed and targeted by CAR T cells when the Firm's proprietary platform immunotherapy, Site-Specific Immunomodulators (SSIs), are used in conjunction as neoadjuvant therapy.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Burnaby, British Columbia, CA V5G 4X4
Reference Number:
172-2018-2019-Q4-924855
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
842333817
Recipient Type:
For-profit organization
Additional Information:
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 92 days. The total amended value is 39,759 dollars.
Amendment Date
Oct 21, 2019
Recipient's Legal Name:
Qu Biologics Inc.
Federal Riding Name:
Burnaby South
Federal Riding Number:
59003
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
541710
Amendments: